Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilke Sipahi

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
The New England Journal of Medicine|April 2, 2015
Duration of dual antiplatelet therapy after drug-eluting stentsIlke Sipahi
JAMA Internal Medicine|June 3, 2014
Coronary artery bypass grafting vs percutaneous coronary intervention in multivessel disease--replyIlke Sipahi
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir|January 4, 2017
What are our tactics for acute heart failure according to TAKTIK?İlke Sipahi
Current Cardiology Reports|January 26, 2015
Bypass grafting versus percutaneous intervention in multivessel coronary disease: the current stateIlke Sipahi
Plos One|March 2, 2022
Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trialsIlke Sipahi
Anadolu Kardiyoloji Dergisi : AKD = the Anatolian Journal of Cardiology|June 27, 2003
[The March 2003 issue of the Anatolian Journal of Cardiology]Ilke Sipahi
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir|March 31, 2016
[Levosimendan in the treatment of acute heart failure; what are you using for patients?]Yüksel Çavuşoğlu, İlke Sipahi
European Heart Journal|September 4, 2007
Arterial remodelling: an independent pathophysiological component of atherosclerotic disease progression and regression. Insights from serial pharmacological intervention trialsPaul Schoenhagen, Ilke Sipahi
Circulation. Arrhythmia and Electrophysiology|April 18, 2013
CRT should be reserved for a QRS duration ≥150 ms: proIlke Sipahi, James C Fang
Heart Failure Clinics|June 5, 2007
Cardiac allograft vasculopathy: an updateIlke Sipahi, Randall C Starling
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
The New England Journal of Medicine|April 2, 2015
Duration of dual antiplatelet therapy after drug-eluting stentsIlke Sipahi
JAMA Internal Medicine|June 3, 2014
Coronary artery bypass grafting vs percutaneous coronary intervention in multivessel disease--replyIlke Sipahi
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir|January 4, 2017
What are our tactics for acute heart failure according to TAKTIK?İlke Sipahi
Current Cardiology Reports|January 26, 2015
Bypass grafting versus percutaneous intervention in multivessel coronary disease: the current stateIlke Sipahi
Plos One|March 2, 2022
Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trialsIlke Sipahi
Anadolu Kardiyoloji Dergisi : AKD = the Anatolian Journal of Cardiology|June 27, 2003
[The March 2003 issue of the Anatolian Journal of Cardiology]Ilke Sipahi
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir|March 31, 2016
[Levosimendan in the treatment of acute heart failure; what are you using for patients?]Yüksel Çavuşoğlu, İlke Sipahi
European Heart Journal|September 4, 2007
Arterial remodelling: an independent pathophysiological component of atherosclerotic disease progression and regression. Insights from serial pharmacological intervention trialsPaul Schoenhagen, Ilke Sipahi
Circulation. Arrhythmia and Electrophysiology|April 18, 2013
CRT should be reserved for a QRS duration ≥150 ms: proIlke Sipahi, James C Fang
Heart Failure Clinics|June 5, 2007
Cardiac allograft vasculopathy: an updateIlke Sipahi, Randall C Starling
Pageof 7